NCT00261456 - The IMPACT Study - Identification of Men With a Genetic Predisposition to ProstAte Cancer | Biotech Hunter

Enrollment

3,500

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

February 28, 2030

Study Completion Date

March 31, 2030

Conditions

Prostate CancerBRCA MutationMismatch Repair Gene MutationGenetic Predisposition to Disease

Interventions

DIAGNOSTIC_TEST

PSA test

Patients tested for their level of Prostate Specific Antigen.

PROCEDURE

Prostate Biopsy

A Prostate biopsy is given as an option to the patient if their PSA level is raised or at the end of 5 years screening.

Trial Locations (1)

Cancer Genetics Unit, Royal Marsden Hospital, Sutton